Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting

Circulation

Volumn 95, Issue 4, 1997, Pages 800-804

  Bode, Christoph ^b   Hanson, Stephen R ^c   Schmedtje Jr , John F ^a   Haber, Edgar ^e   Mehwald, Petra ^b   Kelly, Andrew B ^c,d   Harker, Laurence A ^c   Runge, Marschall S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Medizinische Klinik III   (Germany)

^c Division of Hematology/Oncology   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antibodies; arteries; thrombosis

Indexed keywords

LEPIRUDIN; LU 52369; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BABOON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FIBRIN DEPOSITION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031041684     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.4.800     Document Type: Article

References (21)

1. Meyer BJ, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation. 1994;90:2474-2480.
2. Rubsamen K, Hornberger W, Kirchengast M. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein IIb/IIIa-receptor antagonist RO 43-8857. Thromb Haemost. 1995;74:1353-1360.
3. Rote WE, Mu D-X, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model, II: adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol. 1994;23:203-211.
4. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
5. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995;25:30S-37S.
6. Gold HK, Yasuda T, Jang IK, Guerrero JL, Fallon JT, Leinbach RC, Collen D. Animal models for arterial thrombolysis and prevention of reocclusion: erythrocyte-rich versus platelet-rich thrombus. Circulation. 1991;83(suppl IV):IV-26-IV-40.
7. Haskel EJ, Prager NA, Sobel BE, Abensdschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
8. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. Circulation. 1994;90:1631-1637.
9. Amman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
10. Neuhas KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardioogischer Krankenhausartze (ALKK). Circulation. 1994;90:1638-1642.
11. Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, Von Hodenberg E, Newell JB, Kubler W, Haber E, Runge MS. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation. 1994;90:1956-1963.
12. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA. 1987;84:7659-7662.
13. Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science. 1985;229:765-767.
14. Bode C, Runge MS, Newell JB, Matsueda GR, Haber E. Characterization of an antibody-urokinase conjugate: a plasminogen activator targeted to fibrin. J Biol Chem. 1987;262:10819-10823.
15. Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kubler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation. 1991; 84:805-813.
16. Bode C, Runge MS, Schonermark S, Eberle T, Newell JB, Kubler W, Haber E. Conjugation to antifibrin Fab′ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation. 1990;81:1974-1980.
17. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science. 1983;222:1129-1132.
18. 111indium-labeled platelets in baboons. Blood. 1986;68:386-393.
19. Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw S-Y, Haber E, Hanson SR. Enhanced thrombolyttc and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 1996;94:1412-1422.
20. Cadroy Y, Horbett TA, Hanson SR. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J Lab Clin Med. 1989;113:436-448.
21. Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. J Lab Clin Med. 1989;114: 349-357.